Rep. Gilbert Ray Cisneros, Jr. Buys NeoGenomics, Inc. (NASDAQ:NEO) Shares

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of NeoGenomics, Inc. (NASDAQ:NEO). In a filing disclosed on September 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in NeoGenomics stock on August 7th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 8/28/2026.
• Purchased $15,001 – $50,000 in shares of Quanta Services (NYSE:PWR) on 8/27/2026.
• Purchased $15,001 – $50,000 in shares of Eaton (NYSE:ETN) on 8/27/2026.
• Sold $15,001 – $50,000 in shares of NIKE (NYSE:NKE) on 8/27/2026.
• Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Wheaton Precious Metals (NYSE:WPM) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 8/26/2026.
• Sold $15,001 – $50,000 in shares of Lamar Advertising (NASDAQ:LAMR) on 8/25/2026.
• Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/25/2026.

NeoGenomics Stock Down 1.6%

Shares of NEO traded down $0.29 during mid-day trading on Friday, hitting $17.32. 1,072,034 shares of the company’s stock were exchanged, compared to its average volume of 1,532,019. The stock’s 50-day moving average is $15.91 and its 200-day moving average is $11.75. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.35 and a current ratio of 3.60. NeoGenomics, Inc. has a fifty-two week low of $7.07 and a fifty-two week high of $19.76. The company has a market cap of $2.23 billion, a price-to-earnings ratio of -43.30 and a beta of 1.75.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.02. The firm had revenue of $201.66 million during the quarter, compared to analysts’ expectations of $196.93 million. NeoGenomics had a negative net margin of 6.77% and a negative return on equity of 1.99%. The business’s quarterly revenue was up 11.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.03 earnings per share. On average, sell-side analysts anticipate that NeoGenomics, Inc. will post -0.09 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on NEO shares. Craig Hallum reissued a “buy” rating and set a $19.00 target price on shares of NeoGenomics in a research note on Wednesday, July 29th. Needham & Company LLC raised their target price on NeoGenomics from $15.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. TD Cowen reaffirmed a “buy” rating on shares of NeoGenomics in a report on Wednesday, July 15th. Benchmark increased their price target on shares of NeoGenomics from $11.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Finally, Zacks Research raised shares of NeoGenomics from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $17.67.

Institutional Trading of NeoGenomics

Institutional investors and hedge funds have recently made changes to their positions in the company. First Light Asset Management LLC increased its holdings in shares of NeoGenomics by 26.2% in the 2nd quarter. First Light Asset Management LLC now owns 12,279,523 shares of the medical research company’s stock valued at $179,158,000 after acquiring an additional 2,549,545 shares during the period. First Trust Advisors LP acquired a new stake in NeoGenomics during the 1st quarter worth $45,725,000. Geode Capital Management LLC grew its position in NeoGenomics by 1.4% during the 4th quarter. Geode Capital Management LLC now owns 3,176,644 shares of the medical research company’s stock worth $37,364,000 after purchasing an additional 44,733 shares during the last quarter. Dimensional Fund Advisors LP grew its position in NeoGenomics by 9.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,674,335 shares of the medical research company’s stock worth $19,842,000 after purchasing an additional 225,588 shares during the last quarter. Finally, American Capital Management Inc. increased its stake in NeoGenomics by 120.9% in the third quarter. American Capital Management Inc. now owns 2,345,263 shares of the medical research company’s stock valued at $18,105,000 after purchasing an additional 1,283,390 shares during the period. 98.50% of the stock is owned by hedge funds and other institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

NeoGenomics Company Profile

NeoGenomics, Inc is a provider of cancer-focused diagnostic testing and contract research services. The company operates clinical laboratories that support physicians, hospitals and other healthcare organizations with information used to help diagnose, classify and monitor cancer.

Its testing services include anatomic pathology, immunohistochemistry, flow cytometry, cytogenetics, fluorescence in situ hybridization, molecular testing and next-generation sequencing. NeoGenomics also provides biopharmaceutical companies with clinical trial testing, central laboratory services, biomarker development and other research services intended to support the development of oncology therapies and companion diagnostics.

Founded in 1999, NeoGenomics serves healthcare providers and pharmaceutical and biotechnology customers primarily in the United States, with additional capabilities supporting international clinical research programs.